181 related articles for article (PubMed ID: 29508025)
1. CD137L dendritic cells induce potent response against cancer-associated viruses and polarize human CD8
Dharmadhikari B; Nickles E; Harfuddin Z; Ishak NDB; Zeng Q; Bertoletti A; Schwarz H
Cancer Immunol Immunother; 2018 Jun; 67(6):893-905. PubMed ID: 29508025
[TBL] [Abstract][Full Text] [Related]
2. CD137L-DCs, Potent Immune-Stimulators-History, Characteristics, and Perspectives.
Zeng Q; Zhou Y; Schwarz H
Front Immunol; 2019; 10():2216. PubMed ID: 31632390
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Nickles E; Dharmadhikari B; Yating L; Walsh RJ; Koh LP; Poon M; Tan LK; Wang LZ; Ang Y; Asokumaran Y; Chong WQ; Huang Y; Loh KS; Tay J; Soo R; Koh M; Ho LP; Chan M; Niam M; Soh M; Luah YH; Lim CM; Kaliaperumal N; Au VB; Talib NBSN; Sng R; Connolly JE; Goh BC; Schwarz H
Cancer Immunol Immunother; 2022 Jun; 71(6):1531-1543. PubMed ID: 34661709
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional and functional characterization of CD137L-dendritic cells identifies a novel dendritic cell phenotype.
Harfuddin Z; Dharmadhikari B; Wong SC; Duan K; Poidinger M; Kwajah S; Schwarz H
Sci Rep; 2016 Jul; 6():29712. PubMed ID: 27431276
[TBL] [Abstract][Full Text] [Related]
5. Methods for generating the CD137L-DC-EBV-VAX anti-cancer vaccine.
Nickles E; Xia R; Sun R; Schwarz H
Methods Cell Biol; 2024; 183():187-202. PubMed ID: 38548412
[TBL] [Abstract][Full Text] [Related]
6. CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.
Harfuddin Z; Kwajah S; Chong Nyi Sim A; Macary PA; Schwarz H
Oncoimmunology; 2013 Nov; 2(11):e26859. PubMed ID: 24482752
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
8. CD137 ligand reverse signaling has multiple functions in human dendritic cells during an adaptive immune response.
Lippert U; Zachmann K; Ferrari DM; Schwarz H; Brunner E; Mahbub-Ul Latif AH; Neumann C; Soruri A
Eur J Immunol; 2008 Apr; 38(4):1024-32. PubMed ID: 18395851
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.
Kang SW; Lee SC; Park SH; Kim J; Kim HH; Lee HW; Seo SK; Kwon BS; Cho HR; Kwon B
Cancer Res; 2017 Nov; 77(21):5989-6000. PubMed ID: 28923858
[TBL] [Abstract][Full Text] [Related]
10. Species difference of CD137 ligand signaling in human and murine monocytes.
Tang Q; Jiang D; Shao Z; Martínez Gómez JM; Schwarz H
PLoS One; 2011 Jan; 6(1):e16129. PubMed ID: 21264248
[TBL] [Abstract][Full Text] [Related]
11. Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs.
Zeng Q; Mallilankaraman K; Schwarz H
Front Immunol; 2019; 10():868. PubMed ID: 31068941
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus vaccine therapy with CD137L promotes CD8
Ding J; Jiang N; Zheng Y; Wang J; Fang L; Li H; Yang J; Hu A; Xiao P; Zhang Q; Chai D; Zheng J; Wang G
Pharmacol Res; 2022 Jan; 175():106034. PubMed ID: 34915126
[TBL] [Abstract][Full Text] [Related]
13. Regulation of myelopoiesis by CD137L signaling.
Tang Q; Jiang D; Harfuddin Z; Cheng K; Moh MC; Schwarz H
Int Rev Immunol; 2014; 33(6):454-69. PubMed ID: 24941289
[TBL] [Abstract][Full Text] [Related]
14. A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Ju S; Ju S; Ge Y; Qiu H; Lu B; Qiu Y; Fu J; Liu G; Wang Q; Hu Y; Shu Y; Zhang X
Int Immunol; 2009 Oct; 21(10):1135-44. PubMed ID: 19684160
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo enhancement of antigen-presenting function of dendritic cells and its application for DC-based immunotherapy.
Nieda M; Tomiyama M; Egawa K
Hum Cell; 2003 Dec; 16(4):199-204. PubMed ID: 15147040
[TBL] [Abstract][Full Text] [Related]
18. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cells.
Tomiyama M; Takahara M; Egawa K; Nieda M
Anticancer Res; 2004; 24(5C):3327-33. PubMed ID: 15515428
[TBL] [Abstract][Full Text] [Related]
19. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD137 expression by viral genes reduces T cell costimulation.
Wu M; Wong HY; Lin JL; Moliner A; Schwarz H
J Cell Physiol; 2019 Nov; 234(11):21076-21088. PubMed ID: 31025383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
